Evolution by innovation: improving TCR-Ts for solid tumors

Immuno-Oncology Insights 2023; 4(6), 195–201

DOI: 10.18609/ioi.2023.025

Published: 6 June 2023
Dolores Schendel

How can TCR-based therapeutics learn from the field’s experiences with CAR-T, and better tackle the complex challenges posed by solid tumors? Roisin McGuigan, Editor, Immuno–Oncology Insights, speaks to Dolores Schendel, Chief Scientific Officer, Medigene, about current and future applications of TCR therapies in solid cancers.